nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—HTR2B—Sorafenib—liver cancer	0.503	0.653	CbGbCtD
Dihydroergotamine—ABCB1—Sorafenib—liver cancer	0.104	0.135	CbGbCtD
Dihydroergotamine—ABCB1—Doxorubicin—liver cancer	0.0632	0.082	CbGbCtD
Dihydroergotamine—CYP3A4—Sorafenib—liver cancer	0.0624	0.081	CbGbCtD
Dihydroergotamine—CYP3A4—Doxorubicin—liver cancer	0.0379	0.0491	CbGbCtD
Dihydroergotamine—Myocardial ischaemia—Sorafenib—liver cancer	0.00512	0.0266	CcSEcCtD
Dihydroergotamine—Rash papular—Epirubicin—liver cancer	0.00408	0.0212	CcSEcCtD
Dihydroergotamine—Influenza like illness—Sorafenib—liver cancer	0.004	0.0208	CcSEcCtD
Dihydroergotamine—Rash papular—Doxorubicin—liver cancer	0.00378	0.0196	CcSEcCtD
Dihydroergotamine—Dysphagia—Sorafenib—liver cancer	0.00258	0.0134	CcSEcCtD
Dihydroergotamine—Parosmia—Epirubicin—liver cancer	0.00235	0.0122	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Sorafenib—liver cancer	0.00227	0.0118	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Sorafenib—liver cancer	0.00226	0.0117	CcSEcCtD
Dihydroergotamine—Epistaxis—Sorafenib—liver cancer	0.00217	0.0113	CcSEcCtD
Dihydroergotamine—Parosmia—Doxorubicin—liver cancer	0.00217	0.0113	CcSEcCtD
Dihydroergotamine—Tinnitus—Sorafenib—liver cancer	0.00193	0.01	CcSEcCtD
Dihydroergotamine—Flushing—Sorafenib—liver cancer	0.00192	0.00997	CcSEcCtD
Dihydroergotamine—Rigors—Epirubicin—liver cancer	0.00186	0.00968	CcSEcCtD
Dihydroergotamine—Petechiae—Epirubicin—liver cancer	0.00185	0.00961	CcSEcCtD
Dihydroergotamine—Muscle spasms—Sorafenib—liver cancer	0.00173	0.00899	CcSEcCtD
Dihydroergotamine—Rigors—Doxorubicin—liver cancer	0.00172	0.00896	CcSEcCtD
Dihydroergotamine—Petechiae—Doxorubicin—liver cancer	0.00171	0.00889	CcSEcCtD
Dihydroergotamine—Herpes simplex—Epirubicin—liver cancer	0.00165	0.00858	CcSEcCtD
Dihydroergotamine—Gait disturbance—Epirubicin—liver cancer	0.00156	0.0081	CcSEcCtD
Dihydroergotamine—Hypertension—Sorafenib—liver cancer	0.00155	0.00807	CcSEcCtD
Dihydroergotamine—Arthralgia—Sorafenib—liver cancer	0.00153	0.00796	CcSEcCtD
Dihydroergotamine—Myalgia—Sorafenib—liver cancer	0.00153	0.00796	CcSEcCtD
Dihydroergotamine—Herpes simplex—Doxorubicin—liver cancer	0.00153	0.00793	CcSEcCtD
Dihydroergotamine—Hiccups—Epirubicin—liver cancer	0.00152	0.0079	CcSEcCtD
Dihydroergotamine—Ventricular tachycardia—Epirubicin—liver cancer	0.00152	0.0079	CcSEcCtD
Dihydroergotamine—Vaginal inflammation—Epirubicin—liver cancer	0.00152	0.0079	CcSEcCtD
Dihydroergotamine—Dry mouth—Sorafenib—liver cancer	0.0015	0.00778	CcSEcCtD
Dihydroergotamine—Cystitis noninfective—Epirubicin—liver cancer	0.00149	0.00772	CcSEcCtD
Dihydroergotamine—Salivary hypersecretion—Epirubicin—liver cancer	0.00148	0.00768	CcSEcCtD
Dihydroergotamine—Influenza like illness—Epirubicin—liver cancer	0.00148	0.00768	CcSEcCtD
Dihydroergotamine—Cystitis—Epirubicin—liver cancer	0.00147	0.00763	CcSEcCtD
Dihydroergotamine—Shock—Sorafenib—liver cancer	0.00144	0.00751	CcSEcCtD
Dihydroergotamine—Gait disturbance—Doxorubicin—liver cancer	0.00144	0.00749	CcSEcCtD
Dihydroergotamine—Vaginal infection—Epirubicin—liver cancer	0.00144	0.00746	CcSEcCtD
Dihydroergotamine—Ventricular tachycardia—Doxorubicin—liver cancer	0.00141	0.00731	CcSEcCtD
Dihydroergotamine—Hiccups—Doxorubicin—liver cancer	0.00141	0.00731	CcSEcCtD
Dihydroergotamine—Vaginal inflammation—Doxorubicin—liver cancer	0.00141	0.00731	CcSEcCtD
Dihydroergotamine—Anorexia—Sorafenib—liver cancer	0.0014	0.00727	CcSEcCtD
Dihydroergotamine—Bladder pain—Epirubicin—liver cancer	0.00138	0.00715	CcSEcCtD
Dihydroergotamine—Cystitis noninfective—Doxorubicin—liver cancer	0.00137	0.00714	CcSEcCtD
Dihydroergotamine—Salivary hypersecretion—Doxorubicin—liver cancer	0.00137	0.0071	CcSEcCtD
Dihydroergotamine—Influenza like illness—Doxorubicin—liver cancer	0.00137	0.0071	CcSEcCtD
Dihydroergotamine—Cystitis—Doxorubicin—liver cancer	0.00136	0.00706	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00134	0.00695	CcSEcCtD
Dihydroergotamine—Vaginal infection—Doxorubicin—liver cancer	0.00133	0.0069	CcSEcCtD
Dihydroergotamine—Abnormal vision—Epirubicin—liver cancer	0.00133	0.00689	CcSEcCtD
Dihydroergotamine—Mental disability—Epirubicin—liver cancer	0.00132	0.00686	CcSEcCtD
Dihydroergotamine—Dyspnoea—Sorafenib—liver cancer	0.00131	0.0068	CcSEcCtD
Dihydroergotamine—Dyspepsia—Sorafenib—liver cancer	0.00129	0.00672	CcSEcCtD
Dihydroergotamine—Decreased appetite—Sorafenib—liver cancer	0.00128	0.00663	CcSEcCtD
Dihydroergotamine—Bladder pain—Doxorubicin—liver cancer	0.00127	0.00661	CcSEcCtD
Dihydroergotamine—Fatigue—Sorafenib—liver cancer	0.00127	0.00658	CcSEcCtD
Dihydroergotamine—Pain—Sorafenib—liver cancer	0.00126	0.00652	CcSEcCtD
Dihydroergotamine—Abnormal vision—Doxorubicin—liver cancer	0.00123	0.00638	CcSEcCtD
Dihydroergotamine—Eye pain—Epirubicin—liver cancer	0.00122	0.00635	CcSEcCtD
Dihydroergotamine—Mental disability—Doxorubicin—liver cancer	0.00122	0.00635	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Sorafenib—liver cancer	0.0012	0.00624	CcSEcCtD
Dihydroergotamine—Hot flush—Epirubicin—liver cancer	0.00118	0.00613	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Epirubicin—liver cancer	0.00117	0.00608	CcSEcCtD
Dihydroergotamine—Urticaria—Sorafenib—liver cancer	0.00117	0.00606	CcSEcCtD
Dihydroergotamine—Abdominal pain—Sorafenib—liver cancer	0.00116	0.00603	CcSEcCtD
Dihydroergotamine—Body temperature increased—Sorafenib—liver cancer	0.00116	0.00603	CcSEcCtD
Dihydroergotamine—Eye pain—Doxorubicin—liver cancer	0.00113	0.00588	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Epirubicin—liver cancer	0.00113	0.00585	CcSEcCtD
Dihydroergotamine—Hot flush—Doxorubicin—liver cancer	0.00109	0.00567	CcSEcCtD
Dihydroergotamine—Migraine—Epirubicin—liver cancer	0.00109	0.00565	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Doxorubicin—liver cancer	0.00108	0.00563	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Sorafenib—liver cancer	0.00108	0.00562	CcSEcCtD
Dihydroergotamine—Face oedema—Epirubicin—liver cancer	0.00107	0.00554	CcSEcCtD
Dihydroergotamine—Asthenia—Sorafenib—liver cancer	0.00105	0.00547	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Doxorubicin—liver cancer	0.00104	0.00542	CcSEcCtD
Dihydroergotamine—Pruritus—Sorafenib—liver cancer	0.00104	0.0054	CcSEcCtD
Dihydroergotamine—Migraine—Doxorubicin—liver cancer	0.00101	0.00522	CcSEcCtD
Dihydroergotamine—Diarrhoea—Sorafenib—liver cancer	0.001	0.00522	CcSEcCtD
Dihydroergotamine—Face oedema—Doxorubicin—liver cancer	0.000986	0.00512	CcSEcCtD
Dihydroergotamine—Muscular weakness—Epirubicin—liver cancer	0.000974	0.00506	CcSEcCtD
Dihydroergotamine—Dizziness—Sorafenib—liver cancer	0.000971	0.00505	CcSEcCtD
Dihydroergotamine—Dysphagia—Epirubicin—liver cancer	0.000954	0.00496	CcSEcCtD
Dihydroergotamine—Vomiting—Sorafenib—liver cancer	0.000934	0.00485	CcSEcCtD
Dihydroergotamine—Angina pectoris—Epirubicin—liver cancer	0.00093	0.00483	CcSEcCtD
Dihydroergotamine—Rash—Sorafenib—liver cancer	0.000926	0.00481	CcSEcCtD
Dihydroergotamine—Dermatitis—Sorafenib—liver cancer	0.000925	0.00481	CcSEcCtD
Dihydroergotamine—Headache—Sorafenib—liver cancer	0.00092	0.00478	CcSEcCtD
Dihydroergotamine—Bronchitis—Epirubicin—liver cancer	0.000918	0.00477	CcSEcCtD
Dihydroergotamine—Muscular weakness—Doxorubicin—liver cancer	0.000901	0.00468	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Epirubicin—liver cancer	0.000887	0.00461	CcSEcCtD
Dihydroergotamine—Dysphagia—Doxorubicin—liver cancer	0.000883	0.00459	CcSEcCtD
Dihydroergotamine—Pollakiuria—Epirubicin—liver cancer	0.000882	0.00458	CcSEcCtD
Dihydroergotamine—Nausea—Sorafenib—liver cancer	0.000872	0.00453	CcSEcCtD
Dihydroergotamine—Angina pectoris—Doxorubicin—liver cancer	0.00086	0.00447	CcSEcCtD
Dihydroergotamine—Bronchitis—Doxorubicin—liver cancer	0.000849	0.00441	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Epirubicin—liver cancer	0.000827	0.0043	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000821	0.00426	CcSEcCtD
Dihydroergotamine—Pollakiuria—Doxorubicin—liver cancer	0.000816	0.00424	CcSEcCtD
Dihydroergotamine—Epistaxis—Epirubicin—liver cancer	0.000803	0.00417	CcSEcCtD
Dihydroergotamine—Sinusitis—Epirubicin—liver cancer	0.000798	0.00415	CcSEcCtD
Dihydroergotamine—Rhinitis—Epirubicin—liver cancer	0.000766	0.00398	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Doxorubicin—liver cancer	0.000765	0.00398	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Epirubicin—liver cancer	0.00076	0.00395	CcSEcCtD
Dihydroergotamine—Pharyngitis—Epirubicin—liver cancer	0.000758	0.00394	CcSEcCtD
Dihydroergotamine—Epistaxis—Doxorubicin—liver cancer	0.000743	0.00386	CcSEcCtD
Dihydroergotamine—Sinusitis—Doxorubicin—liver cancer	0.000739	0.00384	CcSEcCtD
Dihydroergotamine—Visual impairment—Epirubicin—liver cancer	0.000736	0.00382	CcSEcCtD
Dihydroergotamine—Tinnitus—Epirubicin—liver cancer	0.000712	0.0037	CcSEcCtD
Dihydroergotamine—Flushing—Epirubicin—liver cancer	0.000709	0.00368	CcSEcCtD
Dihydroergotamine—Rhinitis—Doxorubicin—liver cancer	0.000709	0.00368	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Doxorubicin—liver cancer	0.000703	0.00365	CcSEcCtD
Dihydroergotamine—Pharyngitis—Doxorubicin—liver cancer	0.000701	0.00364	CcSEcCtD
Dihydroergotamine—Chills—Epirubicin—liver cancer	0.000685	0.00356	CcSEcCtD
Dihydroergotamine—Visual impairment—Doxorubicin—liver cancer	0.000681	0.00354	CcSEcCtD
Dihydroergotamine—Tinnitus—Doxorubicin—liver cancer	0.000659	0.00342	CcSEcCtD
Dihydroergotamine—Flushing—Doxorubicin—liver cancer	0.000656	0.00341	CcSEcCtD
Dihydroergotamine—Tension—Epirubicin—liver cancer	0.000652	0.00339	CcSEcCtD
Dihydroergotamine—Nervousness—Epirubicin—liver cancer	0.000646	0.00336	CcSEcCtD
Dihydroergotamine—Muscle spasms—Epirubicin—liver cancer	0.000639	0.00332	CcSEcCtD
Dihydroergotamine—Chills—Doxorubicin—liver cancer	0.000634	0.00329	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Epirubicin—liver cancer	0.000617	0.00321	CcSEcCtD
Dihydroergotamine—Agitation—Epirubicin—liver cancer	0.000611	0.00317	CcSEcCtD
Dihydroergotamine—Tension—Doxorubicin—liver cancer	0.000604	0.00314	CcSEcCtD
Dihydroergotamine—Malaise—Epirubicin—liver cancer	0.0006	0.00312	CcSEcCtD
Dihydroergotamine—Nervousness—Doxorubicin—liver cancer	0.000598	0.0031	CcSEcCtD
Dihydroergotamine—Vertigo—Epirubicin—liver cancer	0.000597	0.0031	CcSEcCtD
Dihydroergotamine—Muscle spasms—Doxorubicin—liver cancer	0.000591	0.00307	CcSEcCtD
Dihydroergotamine—Palpitations—Epirubicin—liver cancer	0.000588	0.00305	CcSEcCtD
Dihydroergotamine—Hypertension—Epirubicin—liver cancer	0.000574	0.00298	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Doxorubicin—liver cancer	0.000571	0.00297	CcSEcCtD
Dihydroergotamine—Arthralgia—Epirubicin—liver cancer	0.000566	0.00294	CcSEcCtD
Dihydroergotamine—Myalgia—Epirubicin—liver cancer	0.000566	0.00294	CcSEcCtD
Dihydroergotamine—Agitation—Doxorubicin—liver cancer	0.000565	0.00294	CcSEcCtD
Dihydroergotamine—Anxiety—Epirubicin—liver cancer	0.000564	0.00293	CcSEcCtD
Dihydroergotamine—Discomfort—Epirubicin—liver cancer	0.000559	0.00291	CcSEcCtD
Dihydroergotamine—Malaise—Doxorubicin—liver cancer	0.000555	0.00288	CcSEcCtD
Dihydroergotamine—Dry mouth—Epirubicin—liver cancer	0.000554	0.00288	CcSEcCtD
Dihydroergotamine—Vertigo—Doxorubicin—liver cancer	0.000553	0.00287	CcSEcCtD
Dihydroergotamine—Confusional state—Epirubicin—liver cancer	0.000547	0.00284	CcSEcCtD
Dihydroergotamine—Palpitations—Doxorubicin—liver cancer	0.000544	0.00282	CcSEcCtD
Dihydroergotamine—Oedema—Epirubicin—liver cancer	0.000543	0.00282	CcSEcCtD
Dihydroergotamine—Shock—Epirubicin—liver cancer	0.000534	0.00277	CcSEcCtD
Dihydroergotamine—Hypertension—Doxorubicin—liver cancer	0.000531	0.00276	CcSEcCtD
Dihydroergotamine—Tachycardia—Epirubicin—liver cancer	0.00053	0.00275	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Epirubicin—liver cancer	0.000525	0.00273	CcSEcCtD
Dihydroergotamine—Arthralgia—Doxorubicin—liver cancer	0.000524	0.00272	CcSEcCtD
Dihydroergotamine—Myalgia—Doxorubicin—liver cancer	0.000524	0.00272	CcSEcCtD
Dihydroergotamine—Anxiety—Doxorubicin—liver cancer	0.000522	0.00271	CcSEcCtD
Dihydroergotamine—Discomfort—Doxorubicin—liver cancer	0.000517	0.00269	CcSEcCtD
Dihydroergotamine—Anorexia—Epirubicin—liver cancer	0.000517	0.00269	CcSEcCtD
Dihydroergotamine—Dry mouth—Doxorubicin—liver cancer	0.000512	0.00266	CcSEcCtD
Dihydroergotamine—Hypotension—Epirubicin—liver cancer	0.000507	0.00263	CcSEcCtD
Dihydroergotamine—Confusional state—Doxorubicin—liver cancer	0.000506	0.00263	CcSEcCtD
Dihydroergotamine—Oedema—Doxorubicin—liver cancer	0.000502	0.00261	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000494	0.00257	CcSEcCtD
Dihydroergotamine—Shock—Doxorubicin—liver cancer	0.000494	0.00257	CcSEcCtD
Dihydroergotamine—Insomnia—Epirubicin—liver cancer	0.000491	0.00255	CcSEcCtD
Dihydroergotamine—Tachycardia—Doxorubicin—liver cancer	0.00049	0.00255	CcSEcCtD
Dihydroergotamine—Paraesthesia—Epirubicin—liver cancer	0.000487	0.00253	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Doxorubicin—liver cancer	0.000485	0.00252	CcSEcCtD
Dihydroergotamine—Dyspnoea—Epirubicin—liver cancer	0.000484	0.00251	CcSEcCtD
Dihydroergotamine—Somnolence—Epirubicin—liver cancer	0.000482	0.00251	CcSEcCtD
Dihydroergotamine—Anorexia—Doxorubicin—liver cancer	0.000479	0.00249	CcSEcCtD
Dihydroergotamine—Dyspepsia—Epirubicin—liver cancer	0.000478	0.00248	CcSEcCtD
Dihydroergotamine—Decreased appetite—Epirubicin—liver cancer	0.000472	0.00245	CcSEcCtD
Dihydroergotamine—Hypotension—Doxorubicin—liver cancer	0.000469	0.00244	CcSEcCtD
Dihydroergotamine—Fatigue—Epirubicin—liver cancer	0.000468	0.00243	CcSEcCtD
Dihydroergotamine—Pain—Epirubicin—liver cancer	0.000464	0.00241	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000457	0.00238	CcSEcCtD
Dihydroergotamine—Insomnia—Doxorubicin—liver cancer	0.000454	0.00236	CcSEcCtD
Dihydroergotamine—Paraesthesia—Doxorubicin—liver cancer	0.000451	0.00234	CcSEcCtD
Dihydroergotamine—Dyspnoea—Doxorubicin—liver cancer	0.000448	0.00233	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Epirubicin—liver cancer	0.000447	0.00232	CcSEcCtD
Dihydroergotamine—Somnolence—Doxorubicin—liver cancer	0.000446	0.00232	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Epirubicin—liver cancer	0.000444	0.00231	CcSEcCtD
Dihydroergotamine—Dyspepsia—Doxorubicin—liver cancer	0.000442	0.0023	CcSEcCtD
Dihydroergotamine—Decreased appetite—Doxorubicin—liver cancer	0.000436	0.00227	CcSEcCtD
Dihydroergotamine—Fatigue—Doxorubicin—liver cancer	0.000433	0.00225	CcSEcCtD
Dihydroergotamine—Urticaria—Epirubicin—liver cancer	0.000431	0.00224	CcSEcCtD
Dihydroergotamine—Pain—Doxorubicin—liver cancer	0.000429	0.00223	CcSEcCtD
Dihydroergotamine—Abdominal pain—Epirubicin—liver cancer	0.000429	0.00223	CcSEcCtD
Dihydroergotamine—Body temperature increased—Epirubicin—liver cancer	0.000429	0.00223	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Doxorubicin—liver cancer	0.000414	0.00215	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Doxorubicin—liver cancer	0.000411	0.00213	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Epirubicin—liver cancer	0.0004	0.00208	CcSEcCtD
Dihydroergotamine—Urticaria—Doxorubicin—liver cancer	0.000399	0.00207	CcSEcCtD
Dihydroergotamine—Body temperature increased—Doxorubicin—liver cancer	0.000397	0.00206	CcSEcCtD
Dihydroergotamine—Abdominal pain—Doxorubicin—liver cancer	0.000397	0.00206	CcSEcCtD
Dihydroergotamine—Asthenia—Epirubicin—liver cancer	0.000389	0.00202	CcSEcCtD
Dihydroergotamine—Pruritus—Epirubicin—liver cancer	0.000384	0.00199	CcSEcCtD
Dihydroergotamine—Diarrhoea—Epirubicin—liver cancer	0.000371	0.00193	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Doxorubicin—liver cancer	0.00037	0.00192	CcSEcCtD
Dihydroergotamine—Asthenia—Doxorubicin—liver cancer	0.00036	0.00187	CcSEcCtD
Dihydroergotamine—Dizziness—Epirubicin—liver cancer	0.000359	0.00186	CcSEcCtD
Dihydroergotamine—Pruritus—Doxorubicin—liver cancer	0.000355	0.00185	CcSEcCtD
Dihydroergotamine—Vomiting—Epirubicin—liver cancer	0.000345	0.00179	CcSEcCtD
Dihydroergotamine—Diarrhoea—Doxorubicin—liver cancer	0.000344	0.00179	CcSEcCtD
Dihydroergotamine—Rash—Epirubicin—liver cancer	0.000342	0.00178	CcSEcCtD
Dihydroergotamine—Dermatitis—Epirubicin—liver cancer	0.000342	0.00178	CcSEcCtD
Dihydroergotamine—Headache—Epirubicin—liver cancer	0.00034	0.00177	CcSEcCtD
Dihydroergotamine—Dizziness—Doxorubicin—liver cancer	0.000332	0.00173	CcSEcCtD
Dihydroergotamine—Nausea—Epirubicin—liver cancer	0.000322	0.00167	CcSEcCtD
Dihydroergotamine—Vomiting—Doxorubicin—liver cancer	0.000319	0.00166	CcSEcCtD
Dihydroergotamine—Rash—Doxorubicin—liver cancer	0.000317	0.00164	CcSEcCtD
Dihydroergotamine—Dermatitis—Doxorubicin—liver cancer	0.000316	0.00164	CcSEcCtD
Dihydroergotamine—Headache—Doxorubicin—liver cancer	0.000315	0.00163	CcSEcCtD
Dihydroergotamine—Nausea—Doxorubicin—liver cancer	0.000298	0.00155	CcSEcCtD
Dihydroergotamine—ADRA2A—Metabolism—MTHFR—liver cancer	1.17e-05	0.000321	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTA1—liver cancer	1.16e-05	0.000317	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PPARA—liver cancer	1.15e-05	0.000315	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NAT2—liver cancer	1.14e-05	0.000313	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	1.14e-05	0.000312	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KDR—liver cancer	1.14e-05	0.000311	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CD—liver cancer	1.14e-05	0.000311	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—PIK3CA—liver cancer	1.14e-05	0.00031	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYCS—liver cancer	1.13e-05	0.00031	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK14—liver cancer	1.13e-05	0.000309	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—PIK3CA—liver cancer	1.13e-05	0.000308	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SERPINE1—liver cancer	1.12e-05	0.000307	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—PIK3CA—liver cancer	1.12e-05	0.000306	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—KRAS—liver cancer	1.11e-05	0.000304	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GGT1—liver cancer	1.11e-05	0.000304	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GOT1—liver cancer	1.11e-05	0.000304	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—RAF1—liver cancer	1.11e-05	0.000304	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—PIK3CA—liver cancer	1.11e-05	0.000304	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ESR1—liver cancer	1.11e-05	0.000303	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—RAF1—liver cancer	1.1e-05	0.000302	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—TP53—liver cancer	1.1e-05	0.0003	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALDOB—liver cancer	1.1e-05	0.0003	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CSF2—liver cancer	1.1e-05	0.0003	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—F2—liver cancer	1.1e-05	0.0003	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—RAF1—liver cancer	1.09e-05	0.000299	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—PIK3CA—liver cancer	1.09e-05	0.000298	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CB—liver cancer	1.09e-05	0.000297	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MTOR—liver cancer	1.09e-05	0.000297	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—H2AFX—liver cancer	1.08e-05	0.000296	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—IL2—liver cancer	1.08e-05	0.000296	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—RAF1—liver cancer	1.08e-05	0.000295	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CB—liver cancer	1.08e-05	0.000294	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MTOR—liver cancer	1.08e-05	0.000294	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CB—liver cancer	1.07e-05	0.000292	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MTOR—liver cancer	1.05e-05	0.000288	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CB—liver cancer	1.05e-05	0.000288	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—HRAS—liver cancer	1.05e-05	0.000287	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CG—liver cancer	1.05e-05	0.000287	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APC—liver cancer	1.05e-05	0.000287	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CRABP1—liver cancer	1.05e-05	0.000286	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—HRAS—liver cancer	1.04e-05	0.000283	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—HRAS—liver cancer	1.03e-05	0.000281	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—PIK3CA—liver cancer	1.02e-05	0.00028	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CDKN1B—liver cancer	1.02e-05	0.000278	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—RAF1—liver cancer	1.01e-05	0.000277	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CDKN1B—liver cancer	1.01e-05	0.000276	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—AKT1—liver cancer	1.01e-05	0.000275	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—HRAS—liver cancer	1.01e-05	0.000275	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—AKT1—liver cancer	1e-05	0.000273	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTP1—liver cancer	9.99e-06	0.000273	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CASP3—liver cancer	9.98e-06	0.000273	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL2—liver cancer	9.97e-06	0.000273	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—liver cancer	9.92e-06	0.000271	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MTOR—liver cancer	9.91e-06	0.000271	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CB—liver cancer	9.91e-06	0.000271	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CASP3—liver cancer	9.91e-06	0.000271	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CDKN1B—liver cancer	9.9e-06	0.000271	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL2—liver cancer	9.89e-06	0.00027	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—BRAF—liver cancer	9.85e-06	0.000269	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CG—liver cancer	9.85e-06	0.000269	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HMOX1—liver cancer	9.85e-06	0.000269	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—liver cancer	9.84e-06	0.000269	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL2—liver cancer	9.82e-06	0.000268	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKT1—liver cancer	9.79e-06	0.000268	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TERT—liver cancer	9.78e-06	0.000267	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCND1—liver cancer	9.72e-06	0.000266	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CASP3—liver cancer	9.7e-06	0.000265	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—JUN—liver cancer	9.7e-06	0.000265	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL2—liver cancer	9.68e-06	0.000265	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCND1—liver cancer	9.64e-06	0.000264	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—liver cancer	9.64e-06	0.000263	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—JUN—liver cancer	9.62e-06	0.000263	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CTNNB1—liver cancer	9.62e-06	0.000263	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CTNNB1—liver cancer	9.55e-06	0.000261	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PPARG—liver cancer	9.51e-06	0.00026	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—HRAS—liver cancer	9.46e-06	0.000259	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCND1—liver cancer	9.44e-06	0.000258	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MMP9—liver cancer	9.43e-06	0.000258	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—JUN—liver cancer	9.42e-06	0.000258	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CDKN1A—liver cancer	9.4e-06	0.000257	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MMP9—liver cancer	9.36e-06	0.000256	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CTNNB1—liver cancer	9.35e-06	0.000256	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CDKN1A—liver cancer	9.33e-06	0.000255	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CDKN1B—liver cancer	9.3e-06	0.000254	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—AKT1—liver cancer	9.27e-06	0.000254	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CD—liver cancer	9.22e-06	0.000252	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKT1—liver cancer	9.2e-06	0.000251	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTM1—liver cancer	9.18e-06	0.000251	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK8—liver cancer	9.17e-06	0.000251	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MMP9—liver cancer	9.17e-06	0.000251	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HPGDS—liver cancer	9.15e-06	0.00025	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKT1—liver cancer	9.15e-06	0.00025	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CDKN1A—liver cancer	9.13e-06	0.00025	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—PIK3CA—liver cancer	9.13e-06	0.00025	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SERPINE1—liver cancer	9.12e-06	0.000249	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CASP3—liver cancer	9.11e-06	0.000249	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK8—liver cancer	9.1e-06	0.000249	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL2—liver cancer	9.1e-06	0.000249	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKT1—liver cancer	9.08e-06	0.000248	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—liver cancer	9.05e-06	0.000248	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—KRAS—liver cancer	9.02e-06	0.000247	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KDR—liver cancer	8.94e-06	0.000245	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK8—liver cancer	8.91e-06	0.000244	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKT1—liver cancer	8.89e-06	0.000243	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK14—liver cancer	8.89e-06	0.000243	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCND1—liver cancer	8.87e-06	0.000242	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—JUN—liver cancer	8.85e-06	0.000242	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CTNNB1—liver cancer	8.78e-06	0.00024	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ESR1—liver cancer	8.72e-06	0.000238	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP1A1—liver cancer	8.7e-06	0.000238	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CD—liver cancer	8.66e-06	0.000237	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—F2—liver cancer	8.61e-06	0.000235	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MMP9—liver cancer	8.61e-06	0.000235	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CDKN1A—liver cancer	8.58e-06	0.000235	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ALB—liver cancer	8.55e-06	0.000234	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—VEGFA—liver cancer	8.47e-06	0.000232	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—VEGFA—liver cancer	8.41e-06	0.00023	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—STAT3—liver cancer	8.39e-06	0.000229	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK8—liver cancer	8.37e-06	0.000229	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKT1—liver cancer	8.35e-06	0.000228	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—STAT3—liver cancer	8.32e-06	0.000228	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PIK3CA—liver cancer	8.29e-06	0.000227	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APC—liver cancer	8.24e-06	0.000225	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CG—liver cancer	8.24e-06	0.000225	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—VEGFA—liver cancer	8.23e-06	0.000225	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—RAF1—liver cancer	8.23e-06	0.000225	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PSMD10—liver cancer	8.16e-06	0.000223	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PSMA4—liver cancer	8.16e-06	0.000223	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—STAT3—liver cancer	8.15e-06	0.000223	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MTHFR—liver cancer	8.11e-06	0.000222	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MTOR—liver cancer	8.03e-06	0.00022	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CB—liver cancer	8.03e-06	0.00022	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARA—liver cancer	7.96e-06	0.000218	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GOT2—liver cancer	7.93e-06	0.000217	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MYC—liver cancer	7.79e-06	0.000213	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TGFB1—liver cancer	7.77e-06	0.000213	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—BRAF—liver cancer	7.74e-06	0.000212	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MYC—liver cancer	7.73e-06	0.000211	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—VEGFA—liver cancer	7.73e-06	0.000211	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TGFB1—liver cancer	7.71e-06	0.000211	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HRAS—liver cancer	7.67e-06	0.00021	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—STAT3—liver cancer	7.66e-06	0.000209	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MYC—liver cancer	7.57e-06	0.000207	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TGFB1—liver cancer	7.55e-06	0.000207	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CB—liver cancer	7.55e-06	0.000206	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CDKN1B—liver cancer	7.54e-06	0.000206	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2E1—liver cancer	7.46e-06	0.000204	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKT1—liver cancer	7.46e-06	0.000204	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CASP3—liver cancer	7.39e-06	0.000202	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL2—liver cancer	7.38e-06	0.000202	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—liver cancer	7.34e-06	0.000201	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CD—liver cancer	7.24e-06	0.000198	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—KRAS—liver cancer	7.2e-06	0.000197	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCND1—liver cancer	7.19e-06	0.000197	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—JUN—liver cancer	7.18e-06	0.000196	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PIK3CA—liver cancer	7.17e-06	0.000196	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SERPINE1—liver cancer	7.16e-06	0.000196	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—KRAS—liver cancer	7.15e-06	0.000195	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CTNNB1—liver cancer	7.12e-06	0.000195	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MYC—liver cancer	7.11e-06	0.000195	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TGFB1—liver cancer	7.1e-06	0.000194	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—KRAS—liver cancer	7.09e-06	0.000194	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—KRAS—liver cancer	7e-06	0.000191	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MMP9—liver cancer	6.98e-06	0.000191	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYCS—liver cancer	6.98e-06	0.000191	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CDKN1A—liver cancer	6.96e-06	0.00019	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GGT1—liver cancer	6.85e-06	0.000187	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GOT1—liver cancer	6.85e-06	0.000187	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CG—liver cancer	6.81e-06	0.000186	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK8—liver cancer	6.79e-06	0.000186	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKT1—liver cancer	6.77e-06	0.000185	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CA—liver cancer	6.62e-06	0.000181	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARG—liver cancer	6.58e-06	0.00018	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—KRAS—liver cancer	6.57e-06	0.00018	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CA—liver cancer	6.57e-06	0.00018	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CA—liver cancer	6.52e-06	0.000178	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RAF1—liver cancer	6.47e-06	0.000177	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CA—liver cancer	6.43e-06	0.000176	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TP53—liver cancer	6.4e-06	0.000175	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TP53—liver cancer	6.35e-06	0.000174	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MTOR—liver cancer	6.31e-06	0.000173	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CB—liver cancer	6.31e-06	0.000173	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—VEGFA—liver cancer	6.27e-06	0.000171	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TP53—liver cancer	6.22e-06	0.00017	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—STAT3—liver cancer	6.21e-06	0.00017	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTP1—liver cancer	6.15e-06	0.000168	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HRAS—liver cancer	6.12e-06	0.000167	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HRAS—liver cancer	6.07e-06	0.000166	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HMOX1—liver cancer	6.07e-06	0.000166	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CA—liver cancer	6.04e-06	0.000165	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HRAS—liver cancer	6.03e-06	0.000165	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CD—liver cancer	5.99e-06	0.000164	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HRAS—liver cancer	5.95e-06	0.000163	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	5.93e-06	0.000162	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALB—liver cancer	5.91e-06	0.000162	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	5.86e-06	0.00016	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—liver cancer	5.86e-06	0.00016	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TP53—liver cancer	5.84e-06	0.00016	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—liver cancer	5.81e-06	0.000159	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CASP3—liver cancer	5.81e-06	0.000159	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL2—liver cancer	5.8e-06	0.000159	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—liver cancer	5.77e-06	0.000158	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MYC—liver cancer	5.77e-06	0.000158	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TGFB1—liver cancer	5.75e-06	0.000157	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—liver cancer	5.69e-06	0.000156	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTM1—liver cancer	5.65e-06	0.000155	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCND1—liver cancer	5.65e-06	0.000155	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—JUN—liver cancer	5.64e-06	0.000154	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	5.6e-06	0.000153	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HRAS—liver cancer	5.59e-06	0.000153	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP9—liver cancer	5.49e-06	0.00015	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	5.47e-06	0.00015	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKT1—liver cancer	5.4e-06	0.000148	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKT1—liver cancer	5.36e-06	0.000147	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP1A1—liver cancer	5.36e-06	0.000147	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—liver cancer	5.35e-06	0.000146	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK8—liver cancer	5.34e-06	0.000146	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KRAS—liver cancer	5.33e-06	0.000146	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKT1—liver cancer	5.32e-06	0.000146	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT1—liver cancer	5.25e-06	0.000144	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CB—liver cancer	5.22e-06	0.000143	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTHFR—liver cancer	5e-06	0.000137	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT1—liver cancer	4.93e-06	0.000135	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—VEGFA—liver cancer	4.93e-06	0.000135	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARA—liver cancer	4.9e-06	0.000134	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CA—liver cancer	4.9e-06	0.000134	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—STAT3—liver cancer	4.88e-06	0.000133	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TP53—liver cancer	4.74e-06	0.00013	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CA—liver cancer	4.6e-06	0.000126	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MYC—liver cancer	4.53e-06	0.000124	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HRAS—liver cancer	4.53e-06	0.000124	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TGFB1—liver cancer	4.52e-06	0.000124	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—liver cancer	4.34e-06	0.000119	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CG—liver cancer	4.2e-06	0.000115	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KRAS—liver cancer	4.19e-06	0.000115	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARG—liver cancer	4.05e-06	0.000111	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT1—liver cancer	4e-06	0.000109	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	3.85e-06	0.000105	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AKT1—liver cancer	3.76e-06	0.000103	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TP53—liver cancer	3.72e-06	0.000102	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CD—liver cancer	3.69e-06	0.000101	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALB—liver cancer	3.64e-06	9.96e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HRAS—liver cancer	3.56e-06	9.74e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—liver cancer	3.41e-06	9.32e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CB—liver cancer	3.22e-06	8.8e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CA—liver cancer	3.18e-06	8.7e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT1—liver cancer	3.14e-06	8.6e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKT1—liver cancer	2.6e-06	7.11e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CA—liver cancer	1.96e-06	5.36e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKT1—liver cancer	1.6e-06	4.38e-05	CbGpPWpGaD
